Abbott Reports 12% Growth in Device Sales

Abbott Laboratories(ABT -8

Additionally, Meanwhile, 25%) reported its second-quarter 2025 results on July 17, 2025, posting 7. 5% organic sales growth (excluding COVID testing), 12% medical device growth, and adjusted EPS of $1. 26, an 11% increase compared to the prior year and a 16% rise compared to the first quarter

The launch of the Volt PFA catheter and the completion of enrollment in the PACIFLEX DUO US trial reflected its rapid innovation cadence in the electrophysiology indication. "In electrophysiology, we had several key accomplishments in the quarter, including dering another quarter of double-digit sales growth, initiating the launch of our new Volt PFA catheter, and completing enrollment ahead of schedule in our PACIFLEX DUO US pivotal trial, given current economic conditions

Furthermore, On the other hand, "— Phil Boudreau, Executive Vice President of Finance & Chief Financial OfficerThese milestones underscore an agile R&D model that rapidly iterates and commercializes next-generation nologies, fortifying Abbott Laboratories' long-term position in high-growth and high-barrier med

However, Sales growth in Latin America region saw growth in the high teens, evidencing demand strength despite regional variance, given current economic conditions. "So really the challenge that we've had is twofold here

Nevertheless, It's really a drop-off on our COVID test sales and some challenges in the China Core Lab market together with some changes that we've seen in the U, in this volatile climate

Additionally, Conversely, Foreign aid funding for HIV testing

Meanwhile, We had expected to see a China recovery in volume

We knew the price impact in China Core Lab, David, and we rolled that into our guidance, in today's market environment

We had expected a market volume recovery to start happening in quite frankly, starting in Q2

We haven't seen that, so we've moved that out and into, you know, into Q4 (remarkable data)

But you put all that together, it's together with the U, given the current landscape

Furthermore, Furthermore, FX, you know, as Phil kind of said in his, is still a headwind versus prior year on the EPS side, but much less of a headwind than what we had originally kind of anticipated back in January and quite frankly, people too

So that helps offset some of the tariff impact

So, yeah, I put this all together, and it'll be nice, David, to see these headwinds behind us next year (which is quite significant)

Nevertheless, And then as you look to next year, you got all this great launch activity across all the es, whether it's Volt in the U, in this volatile climate

Additionally, , Tactiflex Duo internationally, the dual analyte sensor, the launch of the new Alinity system, the biosimilar kind of rollout

So I look at all of that, and I say, okay, in this volatile climate

In contrast, You've got this headwind that we're facing here, amid market uncertainty

Furthermore, Still, we're committing to high single-digit growth and double-digit EPS growth

And then you've got all this kind of great momentum I'm sure we'll talk in other parts of the

Additionally, On the other hand, I know what the consensus is

The evidence shows y look very reasonable to me, in that range of high single digits, double EPS

Meanwhile, It's in line with our historical growth

It's in line with the guidance we've given this year, and it's in line with, you know, what our long-term sustainable growth targets are

So, yeah, it'll be good to see these elements here that I've just kind of highlighted that are specific to diagnostics

And I'll just take it a step further here

Moreover, Furthermore, I mean, you look at our, and I mentioned this in the opening s here

Our Core Lab outside, and I hate doing this, but I think it gets context

Our Latin America region was high teens

Moreover, So our Core Lab is doing very well

In contrast, Alinity is doing very well

We just got this issue that, you know, we're gonna have to go through this year as it relates to VBP and the disruption that happened in our core lab in China

But we're still very bullish on this segment

We still believe it's a very important part of the healthcare system

So I said, looking forward to these headwinds being behind us, and we're well set up for next year. "— Robert Ford, Chairman & Chief Executive OfficerManagement's ability to absorb outsized diagnostics shocks and maintain high-single-digit organic growth reflects strong portfolio diversification and operational discipline amid persistent global market volatility

Nevertheless, Pipeline Momentum and Biosimilars Expand Future Growth PotentialLaunch activity scheduled for Volt in the U

S, Tactiflex Duo internationally, a dual analyte (glucose/ketone) sensor, next-generation Alinity systems, and the debut of biosimilars in key emerging reveal the broad innovation depth in the pipeline, in light of current trends

Abbott's Established Pharmaceutical Division 10 biosimilar submissions to regulators targeting 2026 rollouts. "This's an opportunity for us to really look at how do you sustain that growth rate in this

On the other hand, I think we'll leverage our existing presence in these emerging

We're gonna bring cutting-edge medicines into these countries that I say that historically lack the access

So I think this can be a nice contributor here to our growth in this in the next few years, in this volatile climate

Moreover, "— Robert Ford, Chairman & Chief Executive OfficerCombining established market platforms with new biosimilars leverages Abbott's reach for growth outside mature geographies while requiring relatively limited incremental SG&A investments, enhancing its long-term ROIC spects

Nevertheless, 32 for Q3 and expects a favorable foreign exchange impact of apximately 2% on reported sales, with the full-year FX impact now anticipated to be neutral

Management called the current Street consensus for 2026 "very reasonable," as it expects recent headwinds to abate with pipeline launches supporting acceleration

The analysis reveals article was created using Large Language Models (LLMs) based on The Motley Fool's insights and apach, considering recent developments

It has been reviewed by our AI quality control systems (an important development)

Since LLMs cannot (currently) own stocks, it has no positions in any of the stocks mentioned

The Motley Fool has positions in and recommends Abbott Laboratories

The Motley Fool has a disclosure policy.